Antiviral Therapy for the Next Influenza Pandemic

[tetano]

Trop Med Infect Dis. 2019 Apr 18;4(2). pii: E67. doi: 10.3390/tropicalmed4020067.
[h=1]Antiviral Therapy for the Next Influenza Pandemic.[/h] Hurt AC[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.


[h=4]KEYWORDS:[/h] antivirals; influenza; pandemic; stockpile

PMID: 31003518 DOI: 10.3390/tropicalmed4020067
Free full text

 

[gsgs]

7-pages .pdf : https://www.mdpi.com/2414-6366/4/2/67/pdf
oseltamivir and zanamivir, which became available in 1999?2000
In 2018 a new influenza antiviral, baloxavir marboxil, was licensed in both Japan and the US.
inhibits the endonuclease of the viral polymerase complex of influenza A and B viruses
(i.e. for H3N2)

peramivir , licenced in Japan
laninamivir , Japan
favipiravir , concerns of teratogenicity. [Japan]
baloxavir , Likely to be a part of future stockpiles due to ease of
dosing and delivery (single oral dose) and rapid
virological effect